A new approach to CAR T cell gene engineering using piggyBac transposon and cultivation in the presence of IL-4, IL-7 and IL-21

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F18%3A00011906" target="_blank" >RIV/00023736:_____/18:00011906 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.jcyt.2017.10.001" target="_blank" >https://doi.org/10.1016/j.jcyt.2017.10.001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jcyt.2017.10.001" target="_blank" >10.1016/j.jcyt.2017.10.001</a>

Result language
angličtina
Original language name
A new approach to CAR T cell gene engineering using piggyBac transposon and cultivation in the presence of IL-4, IL-7 and IL-21
Original language description
Clinical-grade CAR19 T cells are routinely manufactured by lentiviral/retroviral (LV/RV) transduction of an anti-CD3/CD28 activated T cells which are then propagated in a culture medium supplemented with IL-2. The use of LV/RVs for T cell modification represents a manufacturing challenge due to the complexity of the transduction approach and the necessity of a thorough quality control. We present here a significantly improved protocol for CAR19 T cell manufacture which is based on the electroporation of PBMCs with plasmid DNA encoding the piggyBac transposon/transposase vectors and their cultivation in the presence of cytokines IL-4, IL-7 and IL-21. We found that activation of CAR receptor either by its cognate ligand (i.e. CD19 expressed on the surface of B cells) or by anti-CAR antibody followed by cultivation in the presence of cytokines IL-4 and IL-7 enables strong and highly selective expansion of functional CAR19 T cells resulting in more than 90% CAR+T cells.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/NV15-34498A" target="_blank" >NV15-34498A: Development of methods for cellular and gene therapy of hematological malignancies.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)